| Amanda Stice, APRN | |
|
2322 S Main St, Fort Scott, KS 66701-3026 | |
| (888) 777-9170 | |
| Not Available |
| Full Name | Amanda Stice |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 2322 S Main St, Fort Scott, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346631462 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 76694 (Kansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Health Center Of Southeast Kansas Inc | 7911816392 | 111 |
News Archive
The research community and pharmaceutical industry have had a long-standing interest in developing peptide-based therapeutics owing to their high target specificity, potent activity, and small size relative to protein-based biologics.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Medizone International, Inc. has filed an international patent application under the auspices of the Patent Co-operation Treaty (PCT) to secure international patent protection for its Asepticsure™ technology. The international patent application consolidates the two previously filed patent applications titled "Healthcare Facility Disinfecting System" and "Disinfecting Process and Apparatus."
A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification of animal insulin and the introduction of human recombinant insulin.
› Verified 8 days ago
| Entity Name | Community Health Center Of Southeast Kansas Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669474425 PECOS PAC ID: 7911816392 Enrollment ID: O20040209000163 |
News Archive
The research community and pharmaceutical industry have had a long-standing interest in developing peptide-based therapeutics owing to their high target specificity, potent activity, and small size relative to protein-based biologics.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Medizone International, Inc. has filed an international patent application under the auspices of the Patent Co-operation Treaty (PCT) to secure international patent protection for its Asepticsure™ technology. The international patent application consolidates the two previously filed patent applications titled "Healthcare Facility Disinfecting System" and "Disinfecting Process and Apparatus."
A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification of animal insulin and the introduction of human recombinant insulin.
› Verified 8 days ago
| Entity Name | Signify Health Medical Associates Of Kansas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780261701 PECOS PAC ID: 8628487998 Enrollment ID: O20210518000551 |
News Archive
The research community and pharmaceutical industry have had a long-standing interest in developing peptide-based therapeutics owing to their high target specificity, potent activity, and small size relative to protein-based biologics.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Medizone International, Inc. has filed an international patent application under the auspices of the Patent Co-operation Treaty (PCT) to secure international patent protection for its Asepticsure™ technology. The international patent application consolidates the two previously filed patent applications titled "Healthcare Facility Disinfecting System" and "Disinfecting Process and Apparatus."
A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification of animal insulin and the introduction of human recombinant insulin.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Stice, APRN Po Box 1832, Pittsburg, KS 66762-1832 Ph: (620) 231-9873 | Amanda Stice, APRN 2322 S Main St, Fort Scott, KS 66701-3026 Ph: (888) 777-9170 |
News Archive
The research community and pharmaceutical industry have had a long-standing interest in developing peptide-based therapeutics owing to their high target specificity, potent activity, and small size relative to protein-based biologics.
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Medizone International, Inc. has filed an international patent application under the auspices of the Patent Co-operation Treaty (PCT) to secure international patent protection for its Asepticsure™ technology. The international patent application consolidates the two previously filed patent applications titled "Healthcare Facility Disinfecting System" and "Disinfecting Process and Apparatus."
A review of published research from the University of Liege, Belgium, reveals a decline in the number of people experiencing allergic reactions to insulin. This is largely due to better purification of animal insulin and the introduction of human recombinant insulin.
› Verified 8 days ago
William T Carl, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2322 S Main St, Fort Scott, KS 66701 Phone: 888-777-9170 | |
Janice J Boge, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 403 Woodland Hills Blvd, Fort Scott, KS 66701 Phone: 620-223-8040 Fax: 620-223-8524 | |
Ms. Judy Nelson, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 188 W 720th Ave, Fort Scott, KS 66701 Phone: 620-362-3351 Fax: 620-362-3352 | |
Gregory J King, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2322 S Main St, Fort Scott, KS 66701 Phone: 620-223-8064 | |
Ryan Lewis, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 202 State St, Ste A, Fort Scott, KS 66701 Phone: 417-321-2845 | |
Anna K O'dell, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2322 S Main St, Fort Scott, KS 66701 Phone: 620-223-8428 Fax: 620-223-5011 |